The recent reduction of live attenuated influenza vaccine (LAIV) effectiveness in multivalent formulations was particularly associated with the A(H1N1)pdm09 component. In the 2017 the WHO vaccine composition committee changed its recommendations for the A(H1N1)pdm09 component to include an A/Michigan/45/2015-like virus. We evaluated effectiveness and quality of newly developed and previous A(H1N1)pdm09 LAIV reassortants through assessment of their thermal and pH stability, receptor binding specificity and replication fitness in primary human airway epithelial cells of nasal origin (hAECN). Our analysis showed that LAIV expressed hemagglutinin (HA) and neuraminidase (NA) from an A/Michigan/45/2015-like strain A/New York/61/2015 (A/New York/61/2015-CDC-LV16A, NY-LV16A), exhibit higher thermal and pH stability compared to the previous vaccine candidates expressing HA and NA from A/California/07/2009 and A/Bolivia/559/2013 (A17/Cal09 and A17/Bol13). Reassortants A/South Africa/3626/2013-CDC-LV14A (SA-LV14A) and NY-LV16A showed preferential binding to α2,6 sialic acid (SA) receptors and replicated at higher titers and more extensively in hAECN compared to A17/Cal09 and A17/Bol13, which had an α2,3 SA receptor binding preference. Our data analysis supports selection of A/New York/61/2015-CDC-LV16A for LAIV formulation and the introduction of new assays for LAIV characterization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668239 | PMC |
| http://dx.doi.org/10.1016/j.jvacx.2019.100031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Optimised Live Attenuated Influenza Vaccine Ferret Efficacy Model Successfully Translates H1N1 Clinical Data.
Vaccines (Basel)
November 2024
Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool L24 9JW, UK.
Article Synopsis
- Between 2013 and 2016, the effectiveness of the A/H1N1pdm09 component in the live attenuated influenza vaccine (LAIV) was lower than expected, prompting a need for better predictive models.
- Researchers optimized the vaccine dose in ferret models and used clinically relevant outcomes, focusing on virus shedding and fever rather than just serum immunogenicity.
- The study found that LAIV formulations with higher vaccine efficacy showed significantly better protection against H1N1 challenges, highlighting the importance of dosing and endpoint selection in evaluating vaccine effectiveness.
Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
Vaccine
January 2023
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India. Electronic address:
Seasonal influenza epidemics cause significant pediatric mortality and morbidity worldwide. Live attenuated influenza vaccines (LAIVs) can be administered intranasally, induce a broad and robust immune response, demonstrate higher yields during manufacturing as compared to inactivated influenza vaccines (IIVs), and thereby represent an attractive possibility for young children in developing countries. We summarize recent pediatric studies evaluating LAIV efficacy in developing countries where a large proportion of the influenza-virus-associated respiratory disease burden occurs.
View Article and Find Full Text PDFStrain development of A/H1N1pdm09 candidate vaccine viruses for the 2021-22 northern hemisphere influenza season.
J Gen Virol
November 2022
Flu-BPD, Biopharmaceuticals Development, R&D, AstraZeneca, Liverpool, UK.
The vaccine effectiveness (VE) of the A/H1N1pdm09 component of the 2017-18 quadrivalent live attenuated influenza vaccine (QLAIV) was improved by performing rational haemagglutinin (HA) mutagenesis. Introducing N125D, D127E, D222G and R223Q substitutions into the HA protein of A/Slovenia/2903/2015 (A/SLOV15) enhanced replicative fitness in primary human nasal epithelial cells (hNECs). This allowed A/SLOV15 to overcome inter-strain competition in QLAIV, resulting in improved VE.
View Article and Find Full Text PDFInfluenza Vaccine Effectiveness: Analysis of the Impact of Repeated Vaccinations in Military Health System Beneficiaries.
Open Forum Infect Dis
October 2022
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Background: Influenza has long burdened the Military Health System (MHS). This study assesses the impact of repeated annual vaccination on influenza vaccine effectiveness (VE).
Methods: This retrospective, case control study using the test-negative design utilized data extracted from the MHS Data Repository (MDR).
Haemagglutinin substitutions N125D, D127E, D222G and R223Q improve replicative fitness and vaccine effectiveness of an A/H1N1pdm09 live attenuated influenza vaccine virus by enhancing α-2,6 receptor binding.
PLoS Pathog
May 2022
Flu-BPD, Biopharmaceuticals R&D, AstraZeneca, Liverpool, United Kingdom.
During 2013-14 and 2015-16, A/H1N1pdm09 live attenuated influenza vaccine (LAIV) viruses replicated inefficiently in primary human nasal epithelial cells (hNEC). This led to reduced vaccine effectiveness (VE) in quadrivalent formulations, mediated by inter-strain competition. By mutating the haemagglutinin (HA) protein, we aimed to enhance hNEC replication of a novel A/H1N1pdm09 vaccine strain to overcome competition and improve VE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!